The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) announced that it will introduce a new regulatory framework to make it easier to manufacture medicines at the point-of-care (POC). Expected to become U.K. law later in 2023, the regulations will cover manufacturing in a range of POC settings, including in relocatable units and even in the home. Source: Genetic Engineering News 1/2/2023